Keywords:
Thyroid / Parathyroids, Ultrasound, Audit and standards, Biopsy, Cancer
Authors:
J. Lee, A. Varma
DOI:
10.26044/ranzcr2022/R-0007
Conclusion
We found that malignancy rates rose with increasing ACR TI-RADS categorisation. These results are somewhat similar to previously quoted malignancy rates ranging from 3.1 - 5% for TI-RADS 3, 5-20% for TI-RADS 4, and >20% for TI-RADS 5 [1, 2, 3].
The periprocedural haematoma rate of 3% was at the lower range of the quoted figures in the literature which ranged from 0.3 – 26% [4].
This study has some limitations, such as being retrospective, limited numbers of patients and sonographic assessment by different operators and different ultrasound machines.
Currently there are many different guidelines that can be used to assess and determine need for biopsy of thyroid nodules. ACR TI-RADS is a reliable classification system that can be used to assess thyroid nodules and reduce the need for unnecessary biopsies.